{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T01:40:25Z","timestamp":1783734025741,"version":"3.55.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T00:00:00Z","timestamp":1708128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007076","name":"Airc Italian Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.biopha.2024.116296","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:03:06Z","timestamp":1708387386000},"page":"116296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["In ovarian cancer maraviroc potentiates the antitumoral activity and further inhibits the formation of a tumor-promoting microenvironment by trabectedin"],"prefix":"10.1016","volume":"172","author":[{"given":"Naike","family":"Casagrande","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Borghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3619-7709","authenticated-orcid":false,"given":"Giuseppe","family":"Corona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4548-3566","authenticated-orcid":false,"given":"Donatella","family":"Aldinucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2024.116296_bib1","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2024.116296_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00280-017-3501-8","article-title":"Advances in ovarian cancer therapy","volume":"81","author":"Cortez","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.biopha.2024.116296_bib3","doi-asserted-by":"crossref","first-page":"s16","DOI":"10.1136\/ijgc-2019-000456","article-title":"Novel therapeutics: response and resistance in ovarian cancer","volume":"29","author":"Zamarin","year":"2019","journal-title":"Int. J. Gynecol. Cancer . J. Int. Gynecol. Cancer Soc."},{"key":"10.1016\/j.biopha.2024.116296_bib4","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1158\/1535-7163.MCT-10-0263","article-title":"A review of trabectedin (ET-743): a unique mechanism of action","volume":"9","author":"D\u2019Incalci","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2024.116296_bib5","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.2174\/1381612828666220526125806","article-title":"Trabectedin in Cancers: Mechanisms and Clinical Applications","volume":"28","author":"Wang","year":"2022","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.biopha.2024.116296_bib6","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/bjc.2014.149","article-title":"Trabectedin, a drug acting on both cancer cells and the tumour microenvironment","volume":"111","author":"D\u2019Incalci","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2024.116296_bib7","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.21873\/anticanres.14385","article-title":"GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer","volume":"40","author":"Selle","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.biopha.2024.116296_bib8","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1002\/ptr.7942","article-title":"Enterolactone and trabectedin suppress epithelial ovarian cancer synergistically via upregulating THBS1","volume":"37","author":"Zeng","year":"2023","journal-title":"Phytother. Res. Ptr."},{"key":"10.1016\/j.biopha.2024.116296_bib9","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1200\/JCO.2009.25.4037","article-title":"Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer","volume":"28","author":"Monk","year":"2010","journal-title":"J. Clin. Oncol. . J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.biopha.2024.116296_bib10","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/stem.1194","article-title":"Autocrine CCL5 signaling promotes invasion and migration of CD133+ ovarian cancer stem-like cells via NF-\u03baB-mediated MMP-9 upregulation","volume":"30","author":"Long","year":"2012","journal-title":"Stem Cells Dayt. Ohio."},{"key":"10.1016\/j.biopha.2024.116296_bib11","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ygyno.2006.01.029","article-title":"Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder","volume":"102","author":"Tsukishiro","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.biopha.2024.116296_bib12","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1158\/0008-5472.CAN-19-1167","article-title":"Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology","volume":"79","author":"Jiao","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2024.116296_bib13","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.3390\/cells12182237","article-title":"The Role and Therapeutic Targeting of CCR5 in Breast Cancer","volume":"12","author":"Hamid","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2024.116296_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s13402-018-0415-3","article-title":"CCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancer","volume":"42","author":"Pervaiz","year":"2019","journal-title":"Cell. Oncol. Dordr."},{"key":"10.1016\/j.biopha.2024.116296_bib15","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1158\/0008-5472.CAN-17-0915","article-title":"CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion","volume":"78","author":"Jiao","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2024.116296_bib16","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3324\/haematol.2018.196725","article-title":"CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth","volume":"104","author":"Casagrande","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2024.116296_bib17","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ccell.2016.03.005","article-title":"Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients","volume":"29","author":"Halama","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2024.116296_bib18","first-page":"112","article-title":"Pembrolizumab and maraviroc in refractory mismatch repair proficient\/microsatellite-stable metastatic colorectal cancer - The PICCASSO phase I trial","volume":"167","author":"Haag","year":"2022","journal-title":"Eur. J. Cancer Oxf. Engl. 1990"},{"key":"10.1016\/j.biopha.2024.116296_bib19","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1124\/dmd.119.087684","article-title":"Interactions between Maraviroc and the ABCB1, ABCG2, and ABCC2 Transporters: An Important Role in Transplacental Pharmacokinetics","volume":"47","author":"Tupova","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2024.116296_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10637-006-7773-9","article-title":"Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype","volume":"25","author":"Beumer","year":"2007","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.biopha.2024.116296_bib21","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/01.cad.0000231480.07654.b5","article-title":"Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer","volume":"17","author":"Hille","year":"2006","journal-title":"Anticancer. Drugs"},{"key":"10.1016\/j.biopha.2024.116296_bib22","article-title":"Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis","volume":"11","author":"Sun","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.biopha.2024.116296_bib23","doi-asserted-by":"crossref","first-page":"6246","DOI":"10.3390\/cancers14246246","article-title":"Mechanisms of Drug Resistance in Ovarian Cancer and Associated Gene Targets","volume":"14","author":"Alatise","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2024.116296_bib24","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1093\/bioinformatics\/btaa102","article-title":"SynergyFinder: a web application for analyzing drug combination dose-response matrix data","volume":"36","author":"Ianevski","year":"2020","journal-title":"Bioinforma. Oxf. Engl."},{"key":"10.1016\/j.biopha.2024.116296_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113261","article-title":"Novel method for fast trabectedin quantification using hydrophilic interaction liquid chromatography and tandem mass spectrometry for human pharmacokinetic studies","volume":"185","author":"Di Gregorio","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.biopha.2024.116296_bib26","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/eji.202149379","article-title":"Inhibition of tumor-associated macrophages by trabectedin improves the antitumor adaptive immunity in response to anti-PD-1 therapy","volume":"51","author":"Belgiovine","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.biopha.2024.116296_bib27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/fon.13.207","article-title":"Trabectedin mechanism of action: what\u2019s new?","volume":"9","author":"D\u2019Incalci","year":"2013","journal-title":"Future Oncol."},{"key":"10.1016\/j.biopha.2024.116296_bib28","doi-asserted-by":"crossref","DOI":"10.4061\/2010\/920161","article-title":"H2AX Phosphorylation: Its Role in DNA Damage Response and Cancer Therapy","volume":"2010","author":"Podhorecka","year":"2010","journal-title":"J. Nucleic Acids"},{"key":"10.1016\/j.biopha.2024.116296_bib29","first-page":"305","volume":"22","author":"Kuo","year":"2008","journal-title":"Gamma-H2AX - a Nov. Biomark. DNA Double-Strand Breaks, Vivo Athens Greece"},{"key":"10.1016\/j.biopha.2024.116296_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2018.101084","article-title":"ROS and the DNA damage response in cancer","volume":"25","author":"Srinivas","year":"2019","journal-title":"Redox Biol."},{"key":"10.1016\/j.biopha.2024.116296_bib31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s13577-021-00642-9","article-title":"3D modeling in cancer studies","volume":"35","author":"Atat","year":"2022","journal-title":"Hum. Cell."},{"key":"10.1016\/j.biopha.2024.116296_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103537","article-title":"ATP-binding cassette efflux transporters and MDR in cancer","volume":"28","author":"Pote","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2024.116296_bib33","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/bjc.1996.151","article-title":"A new method for a quantitative assessment of P-glycoprotein-related multidrug resistance in tumour cells","volume":"73","author":"Homolya","year":"1996","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2024.116296_bib34","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1152\/physrev.00037.2005","article-title":"Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system","volume":"86","author":"Sarkadi","year":"2006","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.biopha.2024.116296_bib35","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/135965350901400514","article-title":"Maraviroc: Pharmacokinetics and drug Interactions","volume":"14","author":"Abel","year":"2009","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.biopha.2024.116296_bib36","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2165\/00003088-200746100-00005","article-title":"Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients","volume":"46","author":"Perez-Ruixo","year":"2007","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.biopha.2024.116296_bib37","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Mokhtari","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2024.116296_bib38","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.3390\/cancers15112972","article-title":"Drug Repurposing in Oncology: A Systematic Review of Randomized Controlled Clinical Trials","volume":"15","author":"Ioakeim-Skoufa","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2024.116296_bib39","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/bjc.2015.407","article-title":"Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin","volume":"113","author":"Colmegna","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2024.116296_bib40","doi-asserted-by":"crossref","first-page":"302","DOI":"10.21873\/cdp.10216","article-title":"Results of a Phase II Trial Testing the Resensitization With Trabectedin in Platinum-resistant Ovarian Cancer","volume":"3","author":"Marquina","year":"2023","journal-title":"Cancer Diagn. Progn."},{"key":"10.1016\/j.biopha.2024.116296_bib41","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.canlet.2020.12.015","article-title":"Trabectedin overcomes doxorubicin-resistance, counteracts tumor-immunosuppressive reprogramming of monocytes and decreases xenograft growth in Hodgkin lymphoma","volume":"500","author":"Casagrande","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2024.116296_bib42","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s12032-015-0607-x","article-title":"CCR5 blockage by maraviroc induces cytotoxic and apoptotic effects in colorectal cancer cells","volume":"32","author":"Pervaiz","year":"2015","journal-title":"Med. Oncol."},{"key":"10.1016\/j.biopha.2024.116296_bib43","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pros.20306","article-title":"Expression of CCL5 (RANTES) and CCR5 in prostate cancer","volume":"66","author":"Vaday","year":"2006","journal-title":"Prostate"},{"key":"10.1016\/j.biopha.2024.116296_bib44","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1158\/1535-7163.MCT-19-1172","article-title":"Autocrine CCL5 Effect Mediates Trastuzumab Resistance by ERK Pathway Activation in HER2-Positive Breast Cancer","volume":"19","author":"Zazo","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2024.116296_bib45","first-page":"81","article-title":"Tumor bud-derived CCL5 recruits fibroblasts and promotes colorectal cancer progression via CCR5-SLC25A24 signaling","volume":"41","author":"Gao","year":"2022","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"10.1016\/j.biopha.2024.116296_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071765","article-title":"The CCL5\/CCR5 Axis in Cancer Progression","volume":"12","author":"Aldinucci","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2024.116296_bib47","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/cam4.1964","article-title":"Association of ABC gene profiles with time to progression and resistance in ovarian cancer revealed by bioinformatics analyses","volume":"8","author":"Seborova","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.biopha.2024.116296_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114542","article-title":"Cancer multidrug-resistance reversal by ABCB1 inhibition: A recent update","volume":"239","author":"Engle","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.biopha.2024.116296_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e11171","article-title":"P-glycoprotein and cancer: what do we currently know?","volume":"8","author":"Pilotto Heming","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.biopha.2024.116296_bib50","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.3390\/cells9051224","article-title":"M2 Macrophages Infiltrating Epithelial Ovarian Cancer Express MDR1: A Feature That May Account for the Poor Prognosis","volume":"9","author":"Badmann","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2024.116296_bib51","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/ijc.29023","article-title":"Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1","volume":"136","author":"Dossi","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2024.116296_bib52","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ccr.2013.01.008","article-title":"Role of Macrophage Targeting in the Antitumor Activity of Trabectedin","volume":"23","author":"Germano","year":"2013","journal-title":"Cancer Cell"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222400177X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222400177X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:54:20Z","timestamp":1760104460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222400177X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":52,"alternative-id":["S075333222400177X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116296","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In ovarian cancer maraviroc potentiates the antitumoral activity and further inhibits the formation of a tumor-promoting microenvironment by trabectedin","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116296","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116296"}}